Shandong Xinhua Pharmaceutical Dirección

Dirección controles de criterios 3/4

El CEO de Shandong Xinhua Pharmaceutical's es Wenhui Xu , nombrado en Sep 2022, tiene una permanencia de 1.67 años. compensación anual total es CN¥1.52M, compuesta por 93.8% salario y 6.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.035% de las acciones de la empresa, por valor de HK$3.47M. La antigüedad media del equipo directivo y de la junta directiva es de 4.4 años y 3.4 años, respectivamente.

Información clave

Wenhui Xu

Chief Executive Officer (CEO)

CN¥1.5m

Compensación total

Porcentaje del salario del CEO	93.8%
Permanencia del CEO	2.1yrs
Participación del CEO	0.04%
Permanencia media de la dirección	4.8yrs
Promedio de permanencia en la Junta Directiva	3.8yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Wenhui Xu en comparación con los beneficios de Shandong Xinhua Pharmaceutical?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	CN¥492m
Mar 31 2024	n/a	n/a	CN¥487m
Dec 31 2023	CN¥2m	CN¥1m	CN¥497m
Sep 30 2023	n/a	n/a	CN¥510m
Jun 30 2023	n/a	n/a	CN¥486m
Mar 31 2023	n/a	n/a	CN¥454m
Jan 01 2023	n/a	n/a	CN¥411m
Sep 30 2022	n/a	n/a	CN¥357m
Jun 30 2022	n/a	n/a	CN¥343m
Mar 31 2022	n/a	n/a	CN¥357m
Dec 31 2021	CN¥1m	n/a	CN¥349m
Sep 30 2021	n/a	n/a	CN¥364m
Jun 30 2021	n/a	n/a	CN¥353m
Mar 31 2021	n/a	n/a	CN¥339m
Dec 31 2020	CN¥829k	n/a	CN¥325m

Compensación vs. Mercado: La compensación total de Wenhui($USD213.16K) está por debajo de la media de empresas de tamaño similar en el mercado Hong Kong ($USD469.55K).

Compensación vs. Ingresos: La compensación de Wenhui ha aumentado más de un 20% en el último año.

CEO

Wenhui Xu (47 yo)

2.1yrs

Permanencia

CN¥1,521,382

Compensación

Mr. Wenhui Xu serves as Executive Director and General Manager of Shandong Xinhua Pharmaceutical Company Limited since October 27, 2022 and September 19, 2022 respectively. He served as the Deputy General...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Tongqing He	Chairman & Deputy GM	3.8yrs	CN¥1.61m	0.043% HK$ 4.1m
Wenhui Xu	GM & Executive Director	2.1yrs	CN¥1.52m	0.035% HK$ 3.4m
Ning Hou	CFO, Financial Controller & Executive Director	10.5yrs	CN¥1.28m	0.048% HK$ 4.6m
Zhonghui Zheng	Deputy General Manager	7.6yrs	CN¥1.41m	0.043% HK$ 4.1m
Changsheng Wei	Deputy GM & Manager of Administrative Personnel Department	no data	CN¥1.41m	0.035% HK$ 3.4m
Xuesong Liu	Deputy General Manager	2.1yrs	CN¥831.80k	0.013% HK$ 1.3m
Changqiu Cao	Company Secretary	27.3yrs	CN¥446.80k	0.029% HK$ 2.8m
Zuxing Kou	Deputy General Manager	2.1yrs	CN¥1.10m	0.011% HK$ 1.0m
Haifeng Guo	Head of Accounting Department	no data	sin datos	sin datos
Xiaohong He	Chief of Finance Department	no data	sin datos	sin datos

4.8yrs

Permanencia media

51yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 719 se considera experimentado (4.4 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Tongqing He	Chairman & Deputy GM	3.8yrs	CN¥1.61m	0.043% HK$ 4.1m
Wenhui Xu	GM & Executive Director	2yrs	CN¥1.52m	0.035% HK$ 3.4m
Ning Hou	CFO, Financial Controller & Executive Director	2yrs	CN¥1.28m	0.048% HK$ 4.6m
Zhichao Tao	Independent Supervisor	22.3yrs	CN¥20.00k	sin datos
Lie Xu	Non-Executive Director	14.3yrs	CN¥1.41m	0.043% HK$ 4.1m
Yanhua Hu	Employee Supervisor	13.3yrs	CN¥57.00k	sin datos
Guangcheng Pan	Independent Non-Executive Director	3.8yrs	CN¥100.00k	sin datos
Chengtong Liu	Chairman of Supervisory Committee	3.8yrs	sin datos	sin datos
Jianwei Zhu	Independent Non-Executive Director	3.8yrs	CN¥100.00k	sin datos
Peixue Ling	Independent Non-Executive Director	2yrs	CN¥58.33k	sin datos
Chengyong Zhang	Non-Independent Director	less than a year	sin datos	sin datos
Ching Ching Cheung	Independent Non-Executive Director	less than a year	sin datos	sin datos

3.8yrs

Permanencia media

54yo

Promedio de edad

Junta con experiencia: La junta directiva de 719 se considera experimentada (3.4 años de antigüedad promedio).

Shandong Xinhua Pharmaceutical Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Shandong Xinhua Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2024

Shandong Xinhua Pharmaceutical Company Limited Announces Executive Changes

Shandong Xinhua Pharmaceutical Company Limited Announces Resignation of Ling Peixue as Independent Non-Executive Director and Member of Strategic Development Committee and Remuneration and Examination Committee

Shandong Xinhua Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2023

Shandong Xinhua Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2023

Less than half of directors are independent

Recent updates

Investor sentiment improves as stock rises 16%

Shandong Xinhua Pharmaceutical Company Limited to Report Q3, 2024 Results on Oct 30, 2024

Shandong Xinhua Pharmaceutical Company Limited Announces Interim Cash Dividend of the Year 2024 of A Shares, Payable on 27 September 2024

Shandong Xinhua Pharmaceutical Company Limited Receives Notification of Approval of Supplementary Drug Application

Shandong Xinhua Pharmaceutical Company Limited Announces Esomeprazole Magnesium Obtains the Notification of Approval of Marketing Application for Chemical Substance Drugs

Upcoming dividend of HK$0.027 per share

Second quarter 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.17 in 2Q 2023)

Shandong Xinhua Pharmaceutical Company Limited Announces Interim Dividend, Payable on or Before 27 September 2024

Shandong Xinhua Pharmaceutical Company Limited Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2023, Payable on 30 July 2024

Shandong Xinhua Pharmaceutical Company Limited to Report First Half, 2024 Results on Aug 23, 2024

Dividend of HK$0.27 announced

Shandong Xinhua Pharmaceutical Company Limited Approves Final Cash Dividend for the Year Ended 31 December 2023, Payable on 30 July 2024

Shandong Xinhua Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2024

First quarter 2024 earnings released: EPS: CN¥0.21 (vs CN¥0.23 in 1Q 2023)

Shandong Xinhua Pharmaceutical Company Limited to Report Q1, 2024 Results on Apr 26, 2024

Full year 2023 earnings released: EPS: CN¥0.74 (vs CN¥0.62 in FY 2022)

Shandong Xinhua Pharmaceutical Company Limited Proposes Final Dividend for the Year Ended 31 December 2023

Shandong Xinhua Pharmaceutical Company Limited Receives Notification of Approval of Application for Marketing of Active Pharmaceutical Ingredient

Now 22% overvalued

Shandong Xinhua Pharmaceutical Company Limited Announces on Memantine Hydrochloride Tablets Obtaining the Drug Registration Certificate

Shandong Xinhua Pharmaceutical Company Limited to Report Fiscal Year 2023 Results on Mar 29, 2024

Shandong Xinhua Pharmaceutical Company Limited Announces Executive Changes

Shandong Xinhua Pharmaceutical Company Limited Receives Drug Registration Certificate of levamlodiping besylate tablets (2.5mg)

Third quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.15 in 3Q 2022)

Shandong Xinhua Pharmaceutical Company Limited Announces Approval of Marketing Application for Chemical Raw Material Drugs for Drugsof Febuxostat

Second quarter 2023 earnings released: EPS: CN¥0.17 (vs CN¥0.13 in 2Q 2022)

Shandong Xinhua Pharmaceutical Company Limited Receives the Drug Registration Certificate of Alogliptin Benzoate Tablets Approved and Issued by the National Medical Products Administration

Shandong Xinhua Pharmaceutical Company Limited Announces Resignation of Ling Peixue as Independent Non-Executive Director and Member of Strategic Development Committee and Remuneration and Examination Committee

Shandong Xinhua Pharmaceutical Company Limited Announces Final Dividend on A Shares for the Year 2022, Payable on July 26, 2023

Shandong Xinhua Pharmaceutical Company Limited Announces Rabeprazole Sodium Enteric-coated Tablets (20mg) Passing the GenericsConsistency Evaluation

Shandong Xinhua Pharmaceutical Company Limited Announces on New Drug Specifications and Passing the Generics Consistency Evaluation

Upcoming dividend of HK$0.22 per share at 3.6% yield

Shandong Xinhua Pharmaceutical Company Limited Obtains Alogliptin Benzoate Approval of Marketing Application for Chemical Raw Material Drugs

Shandong Xinhua Pharmaceutical Company Limited Receives Notice of Approval of Supplementary Drug Application from the National Medical Products Administration

Shandong Xinhua Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2023

Shandong Xinhua Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2023

Full year 2022 earnings released: EPS: CN¥0.62 (vs CN¥0.56 in FY 2021)

Investor sentiment improves as stock rises 24%

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Less than half of directors are independent

Investor sentiment improved over the past week

Shandong Xinhua Pharmaceutical Company Limited Approves Board Appointments

Third quarter 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.14 in 3Q 2021)

Shandong Xinhua Pharmaceutical Company Limited to Report Q3, 2022 Results on Oct 25, 2022

Shandong Xinhua Pharmaceutical Company Limited Announces Board Changes

Second quarter 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.16 in 2Q 2021)

Shandong Xinhua Pharmaceutical Company Limited to Report First Half, 2022 Results on Aug 30, 2022

Shandong Xinhua Pharmaceutical Company Limited Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 05 August 2022

Investor sentiment deteriorated over the past week

Upcoming dividend of HK$0.18 per share

Shandong Xinhua Pharmaceutical Company Limited Announces Resignation of Du Deping as Executive Director and General Manager

Shandong Xinhua Pharmaceutical Company Limited Approves Final Dividend for the Year Ended 31 December 2021, Payable on 5 August 2022

Shandong Xinhua Pharmaceutical Company Limited, Annual General Meeting, Jun 30, 2022

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Less than half of directors are independent

Shandong Xinhua Pharmaceutical Company Limited Proposes to Omit Final Cash Dividend for 2021

Full year 2021 earnings released: EPS: CN¥0.56 (vs CN¥0.52 in FY 2020)

Now 21% undervalued after recent price drop

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.12 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.14 in 2Q 2020)

Shandong Xinhua Pharmaceutical Company Limited announced that it expects to receive CNY 249.999998 million in funding from Hualu Investment Development Co., Ltd.

Full year 2020 earnings released: EPS CN¥0.52 (vs CN¥0.48 in FY 2019)

Shandong Xinhua Pharmaceutical Company Limited to Report Fiscal Year 2020 Results on Mar 31, 2021

New 90-day high: HK$5.40

Investor sentiment improved over the past week